Cd14 pe cy7 clone hcd14

Manufactured by BioLegend

Sourced in Spain

CD14-PE/Cy7 (clone HCD14) is a fluorescently-labeled monoclonal antibody that recognizes the CD14 antigen. CD14 is a glycosylphosphatidylinositol (GPI)-linked protein that serves as a co-receptor for the detection of bacterial lipopolysaccharide (LPS).

Automatically generated - may contain errors

Lab products found in correlation

Cd4 apc clone rpa t4, by BioLegend (2 mentions) Cd3 af700 clone ucht1, by Thermo Fisher Scientific (2 mentions) Cd8 efluor605 clone rpa t8, by Thermo Fisher Scientific (2 mentions) Cd16 af488 clone 3g8, by BioLegend (2 mentions) Cd19 pe cy5 clone hib19, by BioLegend (2 mentions) Cd127 nc650 clone ebiordr5, by Thermo Fisher Scientific (2 mentions) Cd25 apc cy7 clone bc96, by BioLegend (2 mentions) Live dead violet, by Thermo Fisher Scientific (2 mentions) Lsr 2 flow cytometer, by BD (2 mentions) Live deadfixable dead cell stain kit far red, by Thermo Fisher Scientific (1 mentions) 96 well round bottom plate, by BD (1 mentions) Cd3 apc cy7 clone sk7, by BD (1 mentions) Cytochalasin d, by Merck Group (1 mentions) Lsr 2, by BD (1 mentions) Hla dr pe, by BioLegend (1 mentions) Hla dr pe clone l243, by BioLegend (1 mentions)

Close spelling variants of this product

CD14 (clone HCD14, CD14 PE (HCD14) CD14 PE-Cy7 CD14 (HCD14, Clone HCD14 CD14-PE HCD14

3 protocols using cd14 pe cy7 clone hcd14

Leukocyte Uptake of Polymersomes

Check if the same lab product or an alternative is used in the 5 most similar protocols

Isolated
leukocytes (5 × 10⁵, 100 μL) were plated per
well of a sterile 96-well round-bottom plate (Falcon, Corning) and
mixed with 5 μL of BODIPY-labeled polymersomes in a cell:particle
ratio of 1:5 or 1:50. A polymer amount of 0.385 mg was estimated to
correspond to 5 × 10⁹ polymersomes. To block particle
uptake, leukocytes were incubated with Cytochalasin D (Sigma) at a
final concentration of 10 mM for 15 min at 37 °C, prior to adding
polymersomes. The cells were incubated with polymersomes for 30 or
60 min at 37 °C, 250 rpm. Subsequently, the cells were stained
with LIVE/DEAD Fixable Dead Cell Stain Kit-Far Red (Invitrogen) according
to manufacturer’s recommendations and followed by fluorescent
labeling of cell markers: CD45-BV510 (clone HI30, BD Biosciences),
CD14-PE-Cy7 (clone HCD14, Biolegend), CD66b-BV421 (clone G10F5, BD
Biosciences), CD56-PE (clone C5.9, Cytognos, Spain), and CD3-APC-Cy7
(clone SK7, BD Biosciences). Flow cytometry data were collected on
a BD LSR II (BD Biosciences) and analyzed using FlowJo 10.2 Software
(Figure S1). Dead cells and CD45 negative
events were excluded from the data analysis.

van Beek L.F., Welzen P.L., Teufel L.U., Joosten I., Diavatopoulos D.A., van Hest J, & de Jonge M.I. (2021). Bimodal Targeting of Human Leukocytes by Fc- and CpG-Decorated Polymersomes to Tune Immune Induction. Biomacromolecules, 22(10), 4422-4433.

+ Open protocol

+ Expand

Multiparameter Flow Cytometry for PBMC

Check if the same lab product or an alternative is used in the 5 most similar protocols

PBMC were washed and stained with 5 μl Live/Dead Violet (Invitrogen) followed by surface staining with the following titrated antibodies: 0.5 μl CD3-AF700 (clone UCHT1, Ebioscience), 2 μl CD4-APC (clone RPA-T4, BioLegend), 2 μl CD8-Efluor605 (clone RPA-T8, Ebioscience), 2 μl CD14-PE/Cy7 (clone HCD14, BioLegend), 2 μl CD16-AF488 (clone 3G8, BioLegend), 1 μl CD19-PE/Cy5 (clone HIB19, BioLegend), 2 μl CD25-APC/Cy7 (clone BC96, BioLegend), 2 μl CD127-NC650 (clone eBioRDR5, Ebioscience), 15 μl HLA-DR-PE (clone L243 BioLegend). Fluorescence minus one controls were used to set gates for CD25, CD127 and HLA-DR. Samples were acquired on a BD LSR II flow cytometer. Results are presented as percentages of cells after gating out of dead cells and doublets. CD4⁺ and CD8⁺ T cells were identified as CD3⁺ cells, whereas CD14^+/− and CD16^+/− cells were identified as CD3⁻ and CD19⁻ populations. CD25⁺ CD27⁻ populations were gated on the CD4⁺ cells.

Fletcher H.A., Snowden M.A., Landry B., Rida W., Satti I., Harris S.A., Matsumiya M., Tanner R., O'Shea M.K., Dheenadhayalan V., Bogardus L., Stockdale L., Marsay L., Chomka A., Harrington-Kandt R., Manjaly-Thomas Z.R., Naranbhai V., Stylianou E., Darboe F., Penn-Nicholson A., Nemes E., Hatherill M., Hussey G., Mahomed H., Tameris M., McClain J.B., Evans T.G., Hanekom W.A., Scriba T.J, & McShane H. (2016). T-cell activation is an immune correlate of risk in BCG vaccinated infants. Nature Communications, 7, 11290.

+ Open protocol

+ Expand

Multiparametric Immune Profiling of PBMC

Cited 1 time

Check if the same lab product or an alternative is used in the 5 most similar protocols

As previously described (6 (link)), PBMC were washed and stained with 5 μL Live/Dead Violet (Invitrogen) followed by surface staining with the following titrated antibodies: 0.5 μL CD3-AF700 (clone UCHT1, eBioscience), 2 μL CD4-APC (clone RPA-T4, BioLegend), 2 μL CD8-eFluor605 (clone RPA-T8, eBioscience), 2 μL CD14-PE/Cy7 (clone HCD14, BioLegend), 2 μL CD16-AF488 (clone 3G8, BioLegend), 1 μL CD19-PE/Cy5 (clone HIB19, BioLegend), 2 μL CD25-APC/Cy7 (clone BC96, BioLegend), 2 μL CD127-NC650 (clone eBioRDR5, eBioscience), and 15 μL HLA-DR–PE (clone L243, BioLegend). Fluorescence minus one (FMO) controls were used to set gates for CD25, CD127, and HLA-DR. Samples were acquired on a BD LSR II flow cytometer. Results are presented as percentages of cells after excluding dead cells and doublets. CD4⁺ and CD8⁺ T cells were identified as CD3⁺ cells, while CD14^+/− and CD16^+/− cells were identified as CD3⁻ and CD19⁻ populations. CD25⁺CD27⁻ populations were gated on the CD4⁺ cells. The network representation of cell populations positively correlated among all infants was done using the igraph package in R. To identify closely related clusters (communities) within the network, the cluster_optimal function was used, implementing an algorithm described in Brandes et. al.(26 (link)).

Müller J., Tanner R., Matsumiya M., Snowden M.A., Landry B., Satti I., Harris S.A., O’Shea M.K., Stockdale L., Marsay L., Chomka A., Harrington-Kandt R., Thomas Z.R., Naranbhai V., Stylianou E., Mbandi S.K., Hatherill M., Hussey G., Mahomed H., Tameris M., McClain J.B., Evans T.G., Hanekom W.A., Scriba T.J., McShane H, & Fletcher H.A. (2019). Cytomegalovirus infection is a risk factor for tuberculosis disease in infants. JCI Insight, 4(23), e130090.

+ Open protocol

+ Expand

About PubCompare

Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.

We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.

However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.

Ready to get started?

Revolutionizing how scientists
search and build protocols!